U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07292259) titled 'Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia' on Nov. 13.
Brief Summary: Beta thalassemia Major (BTM) is the most common hemoglobinopathy caused by mutations in the beta-globin gene . Worldwide, approximately 80 million people carry thalassemia gene mutation. Around 23,000 babies are affected by BTM each year, of which around 90% belong to low- or middle-income nations.
In Pakistan, the carrier prevalence of thalassemia is 5-7% resulting in a significant population of approximately 10 million carriers in the general population. There are 50,000 thalassemia patients registered in treatment faciliti...